China National Medicines Corporation Ltd.

SHSE:600511 Stock Report

Market Cap: CN¥26.1b

China National Medicines Past Earnings Performance

Past criteria checks 4/6

China National Medicines has been growing earnings at an average annual rate of 9.1%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been growing at an average rate of 4% per year. China National Medicines's return on equity is 12.6%, and it has net margins of 4.2%.

Key information

9.1%

Earnings growth rate

9.3%

EPS growth rate

Healthcare Industry Growth7.0%
Revenue growth rate4.0%
Return on equity12.6%
Net Margin4.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Returns On Capital Signal Tricky Times Ahead For China National Medicines (SHSE:600511)

Dec 01
Returns On Capital Signal Tricky Times Ahead For China National Medicines (SHSE:600511)

We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease

Nov 12
We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 25
The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Sep 26
China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Sep 10
Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Jul 28
Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Jun 24
China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Jun 07
China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Jun 05
Is China National Medicines (SHSE:600511) Using Too Much Debt?

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

May 21
Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

Apr 10
Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

China National Medicines (SHSE:600511) Could Easily Take On More Debt

Feb 28
China National Medicines (SHSE:600511) Could Easily Take On More Debt

Revenue & Expenses Breakdown

How China National Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:600511 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2451,1952,1651,33762
30 Jun 2450,3122,1621,35166
31 Mar 2450,5922,1911,41768
31 Dec 2349,6962,1461,43771
30 Sep 2347,4861,9951,41676
30 Jun 2347,6322,0861,47672
31 Mar 2345,6652,0051,42870
31 Dec 2245,4991,9641,38567
30 Sep 2246,7191,8841,41360
30 Jun 2246,3991,8501,38559
31 Mar 2247,1851,8301,39457
31 Dec 2146,4691,7541,39056
30 Sep 2145,5591,6801,39456
30 Jun 2144,9231,5291,43555
31 Mar 2142,5121,4491,44553
31 Dec 2040,3791,3831,41352
30 Sep 2041,0461,5371,42662
30 Jun 2041,1531,4691,41852
31 Mar 2042,8051,5491,41550
31 Dec 1944,6441,6041,48945
30 Sep 1942,6731,5251,44342
30 Jun 1940,9911,5231,41442
31 Mar 1939,6591,4361,42437
31 Dec 1838,7401,4041,45734
30 Sep 1837,9941,2561,42422
30 Jun 1837,4521,2241,36330
31 Mar 1836,6531,1631,17625
31 Dec 1736,2851,1411,00222
30 Sep 1736,0721,06091810
30 Jun 1735,5401,0448230
31 Mar 1740,1031,1019670
31 Dec 1634,6119908510
30 Sep 1628,6138876750
30 Jun 1622,8137525940
31 Mar 1612,4085273850
31 Dec 1512,0785133810
30 Sep 1512,0654994150
30 Jun 1511,8944993850
31 Mar 1511,7734903970
31 Dec 1411,5384833900
30 Sep 1411,1774653910
30 Jun 1410,8244573880
31 Mar 1410,4084313660
31 Dec 1310,0814123590

Quality Earnings: 600511 has high quality earnings.

Growing Profit Margin: 600511's current net profit margins (4.2%) are higher than last year (4.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 600511's earnings have grown by 9.1% per year over the past 5 years.

Accelerating Growth: 600511's earnings growth over the past year (8.5%) is below its 5-year average (9.1% per year).

Earnings vs Industry: 600511 earnings growth over the past year (8.5%) exceeded the Healthcare industry -5.7%.

Return on Equity

High ROE: 600511's Return on Equity (12.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 07:53
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

China National Medicines Corporation Ltd. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Yanyin ZhuChina International Capital Corporation Limited
Ying LuoChina Merchants Securities Co. Ltd.